Αποτελέσματα αναζήτησης - "CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA"

Relation: SOARES, Roniel Víctor Alves. Análise e aplicação da ferramenta de bioinformática geo cancer prognostic dataset retriever em dados genômicos gene expression omnibus (GEO) para prognósticos de câncer. 2023. 24f. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) – Universidade Federal de Uberlândia, Patos de Minas, 2023.; https://repositorio.ufu.br/handle/123456789/39634

Διαθεσιμότητα: https://repositorio.ufu.br/handle/123456789/39634

View record from BASE

6

Identification of mutations potentially associated with Chemoradiotherapy Treatment response in cervical cancer

Συγγραφείς: Facciolo Filho, Antonio Carlos

Συνεισφορές: Alves, Tamires Caixeta, http://lattes.cnpq.br/8597119747634649, Gomes, Matheus de Souza, http://lattes.cnpq.br/8674610062329213, Melo, Carolina Pereira de Souza, http://lattes.cnpq.br/4478543227984173, Araújo, Carlos Bruno, http://lattes.cnpq.br/7810817113256976

Θεματικοί όροι: Cervical cancer, RNA-seq, Chemoradiotherapy, Somatic mutations, MUC6, NAP1L1, PABPC1, NLRP4, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA

Περιγραφή αρχείου: application/pdf

Relation: FACCIOLO FILHO, Antonio Carlos. Identification of mutations potentially associated with Chemoradiotherapy Treatment response in cervical cancer. 2023. 42 f. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) – Universidade Federal de Uberlândia, Uberlândia, 2023.; https://repositorio.ufu.br/handle/123456789/38461

Διαθεσιμότητα: https://repositorio.ufu.br/handle/123456789/38461

View record from BASE

7

Dissertation/ Thesis

Avaliação biológica de candidatos a metalofármacos associados à Zinco(II) em linhagens celulares de câncer de mama ; Biological evaluation of candidates for metallodrugs associated with Zinc(II) in breast cancer cell lines

Συγγραφείς: Machado, Raiane Aparecida dos Santos

Συνεισφορές: http://lattes.cnpq.br/7092893236728387, Araújo, Thaise Gonçalves de, http://lattes.cnpq.br/3348615812243880, Júnior, Celso Oliveira Rezende, http://lattes.cnpq.br/7220061875015002, Moreira, Gabriela Alves, http://lattes.cnpq.br/9128531718627282

Θεματικοί όροι: Câncer de mama, Complexos metálicos, Zinco, Sinergismo, Vitamina D, Câncer de mama triplo negativo, Breast cancer, Metallic compounds, Zinc, Synergism, D vitamin, Triple negative breast cancer, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, Biotecnologia, Mamas - Câncer, Zinco - Efeito fisiológico, Câncer - Tratamento, ODS::ODS 3. Saúde e bem-estar - Assegurar uma vida saudável e promover o bem-estar para todos, em todas as idades

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufu.br/handle/123456789/41379; http://doi.org/10.14393/ufu.di.2024.37

Διαθεσιμότητα: https://repositorio.ufu.br/handle/123456789/41379
https://doi.org/10.14393/ufu.di.2024.37

View record from BASE

8

Dissertation/ Thesis

Desafios do diagnóstico molecular da síndrome de Silver-Russell ; Challenges of the molecular diagnosis of Russell-Silver Syndrome

Συγγραφείς: Barbalho, Hozana Beatriz Dantas

Συνεισφορές: Ferreira, Leonardo Capistrano, orcid:0009-0007-2064-2034, http://lattes.cnpq.br/5975087350618642, orcid:0000-0001-9268-4881, http://lattes.cnpq.br/2739353650933389, Castro, Matheus Augusto Araújo, orcid:0000-0003-0335-8799, http://lattes.cnpq.br/4770111686982259, Freire Neto, Francisco Paulo, orcid:0000-0003-2394-2773, http://lattes.cnpq.br/8004536021600117

Θεματικοί όροι: Epigenética, Síndrome de Silver-Russell, Diagnóstico Molecular, MS-MLPA, Epigenetics, Russell-Silver Syndrome, Molecular Diagnosis, CNPQ::CIENCIAS BIOLOGICAS, CNPQ::CIENCIAS BIOLOGICAS::GENETICA, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufrn.br/handle/123456789/54035

Διαθεσιμότητα: https://repositorio.ufrn.br/handle/123456789/54035

View record from BASE

9

Dissertation/ Thesis

Expressão de IFN, IL-17 e HERVs, e níveis séricos de IL-2, CCL2 e CCL3 associados à gravidade da COVID-19. ; Expression of IFN, IL-17 and HERVs, and serum levels of IL-2, CCL2 and CCL3 associated with the severity of COVID-19.

Συγγραφείς: Gondim, Taiane de Macêdo

Συνεισφορές: Trindade, Soraya de Castro, orcid:0000-0001-7125-9114, http://lattes.cnpq.br/4927186541075656, Silva, Marcos da Costa, orcid:0000-0002-3809-0297, http://lattes.cnpq.br/0296368326522374, Vale, Vera Lúcia Costa, orcid:0000-0002-4055-5049, http://lattes.cnpq.br/5067432422569443

Θεματικοί όροι: Coronavírus, COVID-19, Citocinas, Inflamação, Coronavirus, Cytokines, Inflammation, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, CNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIA

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufba.br/handle/ri/38481

Διαθεσιμότητα: https://repositorio.ufba.br/handle/ri/38481

View record from BASE

10

Dissertation/ Thesis

Identificação de mecanismos genéticos e imunológicos associados ao uso nocivo de álcool em uma população latino-americana miscigenada

Συγγραφείς: Amaral, Edson Henrique Bispo

Συνεισφορές: Oliveira, Pablo Rafael Silveira, orcid:0000-0001-9541-3737, http://lattes.cnpq.br/0858029972032771, Britto, Gabriela de Sales Guerreiro, orcid:0000-0001-9853-7284, http://lattes.cnpq.br/5188404079223506, Silva, Thiago Magalhães da, http://lattes.cnpq.br/1410457468493590, Feitosa, Caroline Alves, http://lattes.cnpq.br/9443073808622495

Θεματικοί όροι: GWAS, Comportamento, Álcool, Imunologia, Behavior, Alcohol, Immunology, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, CNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOGENETICA

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufba.br/handle/ri/37744

Διαθεσιμότητα: https://repositorio.ufba.br/handle/ri/37744

View record from BASE

11

Dissertation/ Thesis

Caracterização clínica e molecular de pacientes com carcinoma medular de tireoide do estado da Bahia ; Clinical and molecular characterization of patients with medullary carcinoma of the thyroid in the state of Bahia

Συγγραφείς: Matta, Rafael Reis Campos da

Συνεισφορές: Ramos, Helton Estrela, orcid:0000-0002-2900-2099, http://lattes.cnpq.br/5624505454133902, Cerqueira, Taíse Lima de Oliveira, http://lattes.cnpq.br/0365632293236220, Carvalho, Acacia Fernandes Lacerda de, orcid:0000-0003-3639-338X, http://lattes.cnpq.br/8227096712575197, Camacho, Cléber Pinto, orcid:0000-0002-8653-0031, http://lattes.cnpq.br/1832800364435894

Θεματικοί όροι: Carcinoma medular, Mutação, Polimorfismo de nucleotídeo único, Tireoidectomia, Medullary carcinoma, Mutation, Single-nucleotide polymorphism, Thyroidectomy, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA

Περιγραφή αρχείου: application/pdf

Relation: 1. Deng Y, Li H, Wang M, Li N, Tian T, Wu Y, et al. Global burden of thyroid cancer from 1990 to 2017. JAMA Netw Open. 2020;3(6):e208759. doi:10.1001/jamanet workopen.2020.8759 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi:10.3322/caac.21660 3. Instituto Nacional de Câncer José Alencar Gomes Da Silva. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2022. Disponível em: https://www.inca.gov.br/estimativa 4. World Health Organization. Classification of tumours. Endocrine tumours. Lyon: International Agency for Research on Cancer; 2022. Disponível em: https://tumourclassification.iarc.who.int/welcome/ 5. Czarniecka A, Oczko-Wojciechowska M, Hajduk A, Zeman M, Jarzab B. Current surgical management in RET mutation carriers. Endokrynol Pol. 2019;70(4):367-79. doi:10.5603/EP.a2019.0021 6. Kawai K, Takahashi M. Intracellular RET signaling pathways activated by GDNF. Cell Tissue Res. 2020;382(1):113-23. doi:10.1007/s00441-020-03262-1 7. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581-88. doi:10.1016/0092-8674(85)90115-1 8. Raue F, editor. Medullary thyroid carcinoma. Recent results cancer res. Cham: Springer International Publishing; 2015. 204 p. doi.org/10.1007/978-3-319-22542-5 9. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367(6461):375-6. doi:10.1038/367375a0. 10. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139-48. doi:10.1002/(sici)1097-0142(20000301)88:53.0.co;2-z. 11. Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, et al. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf). 2011;74(2):241-7. doi:10.1111/j.1365-2265.2010.03900.x 12. Simbolo M, Mian C, Barollo S, Fassan M, Mafficini A, Neves D, et al. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. Virchows Arch. 2014;465(1):73-8. doi:10.1007/s00428-014-1589-3. 13. Wei S, LiVolsi VA, Montone KT, Morrissette JJ, Baloch ZW. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience. Endocr Pathol. 2016;27(4):359-362. doi:10.1007/s12022-016-9446-3. 14. Romei C, Casella F, Tacito A, Bottici V, Valerio L, Viola D, et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J Med Genet. 2016;53(11):729-734. doi:10.1136/jmedgenet-2016-103833. 15. Hedayati M, Zarif Yeganeh M, Sheikholeslami S, Afsari F. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer. Crit Rev Clin Lab Sci. 2016;53(4):217-27. doi:10.3109/10408363.2015.1129529. 16. Qu N, Shi X, Zhao JJ, Guan H, Zhang TT, Wen SS, et al. Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma. Thyroid. 2020;30(7):1025-1036. doi:10.1089/thy.2019.0531. 17. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531-44. doi:10.1089/thy.2005.15.531. 18. Wells AS Junior, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-10. doi:10.1089/thy.2014.0335 19. Chen H, Sippel RS, O'Dorisio MS, Vinick AI, Lloyd RV, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775-83. doi:10.1097/ MPA.0b013e3181ebb4f0 20. Maia AL, Siqueira DR, Kulcsar MA, Tincani AJ, Mazeto GM, Maciel LM. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2014;58(7):667-700. doi:10.1590/0004-2730000003427 21. Viola D, Elisei R. Management of Medullary Thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48(1):285-301. doi:10.1016/j.ecl.2018.11.006 22. Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS, Schneider DF, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017;161(1):137-46. doi:10.1016/ j.surg.2016.04.053 23. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79(3):564-73. doi:10.1002/(sici)1097-0142(19970201)79:33.0.co;2-0 24. Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma. JAMA Surg. 2018;153(1):52-9. doi:10.1001/jamasurg.2017.3555 25. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9(4):225-234. doi:10.1016/S2213-8587(21)00027-9 26. Sierra MS, Soerjomataram I, Forman D. Thyroid cancer burden in Central and South America. Cancer Epidemiol. 2016;44 Suppl 1:S150-S157. doi:10.1016/j.canep.2016.07.017 27. Borges AKDM, Ferreira JD, Koifman S, Koifman RJ. Thyroid cancer in Brazil: a descriptive study of cases held on hospital-based cancer registries, 2000-2016. Epidemiol Serv Saude. 2020;29(4):e2019503. doi:10.5123/s1679-49742020000400012 28. Ceolin L, Duval MADS, Benini AF, Ferreira CV, Maia AL. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer. 2019;26(9):R499-R518. doi:10.1530/ERC-18-0574 29. Ball DW. Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am. 2007;36(3):823-viii. doi:10.1016/j.ecl.2007.04.001 30. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539-47. doi:10.1634/theoncologist.2007-0239 31. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18(10):1093-100. doi:10.1634/theoncologist.2013-0053 32. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299-310. doi:10.1111/j.1365-2265.2004.02037.x 33. Fussey JM, Vaidya B, Kim D, Clark J, Ellard S, Smith JA. The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: a systematic review. Clin Endocrinol (Oxf). 2019;91(6):697-707. doi:10.1111/cen.14060 34. Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98(8):3149-64. doi:10.1210/jc.2013-1204 35. Newey PJ. Multiple endocrine neoplasia. Medicine. 2021;49(9):539-43. doi.org/10.1016/j.mpmed.2021.06.003 36. Mathiesen JS, Effraimidis G, Rossing M, Rasmussen AK, Hoejberg L, Bastholt L, et al. Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol. 2022;79:163-79. doi:10.1016/j.semcancer.2021.03.035 37. Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer. 2010;9(3):449-57. doi:10.1007/s10689-010-9320-2 38. Scapineli JO, Ceolin L, Puñales MK, Dora JM, Maia AL. MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics. Fam Cancer. 2016;15(4):625-33. doi:10.1007/s10689-016-9892-6 39. Coyle D, Friedmacher F, Puri P. The association between Hirschsprung's disease and multiple endocrine neoplasia type 2a: a systematic review. Pediatr Surg Int. 2014;30(8):751-6. doi:10.1007/s00383-014-3538-2 40. Castinetti F, Waguespack SG, Machens A, Uchino S, Hasse-Lazar K, Sando G, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213-20. doi:10.1016/S2213-8587(18)30336-X 41. Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64-71. doi:10.1016/S2213-8587(15)00337-X 42. Niederle MB, Scheuba C, Riss P, Selberherr A, Koperek O, Niederle B. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays? Thyroid. 2020;30(7):974-984. doi:10.1089/thy.2019.0785. 43. Park H, Park J, Choi MS, Kim J, Kim H, Shin JH, et al. Preoperative Serum Calcitonin and Its Correlation with Extent of Lymph Node Metastasis in Medullary Thyroid Carcinoma. Cancers (Basel). 2020;12(10):2894. doi:10.3390/cancers12102894. 44. Turkdogan S, Forest VI, Hier MP, Tamilia M, Florea A, Payne RJ. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer. J Otolaryngol Head Neck Surg. 2018;47(1):55. doi:10.1186/s40463-018-0303-x 45. Pacini F, Castagna MG, Cipri C, Schumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):475-85. doi:10.1016/j.clon.2010.05.002 46. Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg. 2007;142(3):289-94. doi:10.1001/archsurg.142.3.289 47. Buzdugă CM, Costea CF, Cărăuleanu A, Lozneanu L, Turliuc MD, Cucu AI, et al. Protean cytological, histological and immunohistochemical appearances of medullary thyroid carcinoma: current updates. Rom J Morphol Embryol. 2019;60(2):369-81. 48. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):15-31. doi:10.1016/j.beem.2007.01.004 49. Agarwal S, Bychkov A, Jung CK. Emerging Biomarkers in thyroid practice and research. Cancers (Basel). 2021;14(1):204. doi:10.3390/cancers14010204 50. Tisell LE, Oden A, Muth A, Altiparmak G, Mõlne J, Ahlman H, et al. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003;89(11):2093-7. doi:10.1038/sj.bjc.6601453 51. Mian C, Pennelli G, Barollo S, Altiparmak G, Mõlne J, Ahlman H, et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol. 2011;164(6):971-6. doi:10.1530/EJE-11-0079 52. Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Mohamed-Amine B, et al. International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol. 2022;40(1):96-104. doi:10.1200/JCO.21.01329 53. Takahashi M. Structure and expression of the ret transforming gene. IARC Sci Publ. 1988;(92):189-97. 54. Avantaggiato V, Dathan NA, Grieco M, Fabien N, Lazzaro D, Fusco A, et al. Developmental expression of the RET protooncogene. Cell Growth Differ. 1994;5(3):305-11. 55. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994;367(6461):380-83. doi:10.1038/367380a0 56. Ikeda I, Ishizaka Y, Tahira T, Suzuki T, Onda M, Sugimura T, et al. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene. 1990;5(9):1291-6. 57. Santoro M, Rosati R, Grieco M, Berlingieri MT, D'Amato GL, Franciscis V de, et al. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene. 1990;5(10):1595-8. 58. Takahashi M, Buma Y, Taniguchi M. Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene. 1991;6(2):297-301. 59. Pasini B, Hofstra RM, Yin L, et al. The physical map of the human RET proto-oncogene. Oncogene. 1995;11(9):1737-1743. 60. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 1988;3(5):571-8. 61. Iwamoto T, Taniguchi M, Asai N, Ohkusu K, Nakashima I, Takahashi M. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene. 1993;8(4):1087-91. 62. Sugaya R, Ishimaru S, Hosoya T, Saigo K, Emori Y. A Drosophila homolog of human proto-oncogene ret transiently expressed in embryonic neuronal precursor cells including neuroblasts and CNS cells. Mech Dev. 1994;45(2):139-45. doi:10.1016/0925-4773(94)90027-2 63. Marcos-Gutiérrez CV, Wilson SW, Holder N, Pachnis V. The zebrafish homologue of the ret receptor and its pattern of expression during embryogenesis. Oncogene. 1997;14(8):879-89. doi:10.1038/sj.onc.1201048 64. Hahn M, Bishop J. Expression pattern of Drosophila ret suggests a common ancestral origin between the metamorphosis precursors in insect endoderm and the vertebrate enteric neurons. Proc Natl Acad Sci USA. 2001;98(3):1053-8. doi:10.1073/ pnas.98.3.1053 65. Machens A, Lorenz K, Dralle H. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities. J Intern Med. 2009;266(1):114-25. doi:10.1111/j.1365-2796.2009.02113.x 66. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010;16(24):5936-41. doi:10.1158/1078-0432.CCR-09-0786 67. Anders J, Kjar S, Ibáñez CF. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem. 2001;276(38):35808-17. doi:10.1074/jbc.M104968200 68. Mahato AK, Sidorova YA. RET receptor tyrosine kinase: role in neurodegeneration, obesity, and cancer. Int J Mol Sci. 2020;21(19):7108. doi:10.3390/ijms21197108 69. Ibáñez CF. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol. 2013;5(2):a009134. doi:10.1101/cshperspect.a009134 70. Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M. Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene. 1993;8(11):2925-9. 71. Rochette L, Zeller M, Cottin Y, Vergely C. Insights into mechanisms of GDF15 and receptor gfral: therapeutic targets. Trends Endocrinol Metab. 2020;31(12):939-51. doi:10.1016/j.tem.2020.10.004 72. Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene. 1990;5(1):97-102. 73. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene. 1995;11(10):2039-45. 74. Carter MT, Yome JL, Marcil MN, Martin CA, Vanhorne JB, Mulligan LM. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function. Cytogenet Cell Genet. 2001;95(3-4):169-176. doi:10.1159/000059341 75. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development. 1993;119(4):1005-17. doi:10.1242/dev.119.4.1005 76. Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene. 1995;10(1):191-8. 77. Trupp M, Belluardo N, Funakoshi H, Ibáñez CF. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci. 1997;17(10):3554-67. doi:10.1523/JNEUROSCI.17-10-03554.1997 78. Bennett DL, Michael GJ, Ramachandran N, Munson JB, Averill S, Yan Q, et al. A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury. J Neurosci. 1998;18(8):3059-72. doi:10.1523/JNEUROSCI.18-08-03059.1998 79. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett. 2004;204(2):197-211. doi:10.1016/S0304-3835(03)00456-7 80. Schuchardt A, D'Agati V, Pachnis V, Costantini F. Renal agenesis and hypodysplasia in ret-k- mutant mice result from defects in ureteric bud development. Development. 1996;122(6):1919-29. doi:10.1242/dev.122.6.1919 81. Chi X, Michos O, Shakya R, Riccio P, Enomoto H, Licht JD, et al. Ret-dependent cell rearrangements in the wolffian duct epithelium initiate ureteric bud morphogenesis. Dev Cell. 2009;17(2):199-209. doi:10.1016/j.devcel.2009.07.013 82. Davis TK, Hoshi M, Jain S. To bud or not to bud: the RET perspective in CAKUT. Pediatr Nephrol. 2014;29(4):597-608. doi:10.1007/s00467-013-2606-5 83. Meng X, Lindahl M, Hyvönen ME, Parvinen M, Rooij MD de, Hess MW, et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science. 2000;287(5457):1489-93. doi:10.1126/science.287.5457.1489 84. Naughton CK, Jain S, Strickland AM, Gupta A, Milbrandt J. Glial cell-line derived neurotrophic factor-mediated RET signaling regulates spermatogonial stem cell fate. Biol Reprod. 2006;74(2):314-21. doi:10.1095/biolreprod.105.047365 85. Jijiwa M, Kawai K, Fukihara J, Nakamura A, Hasegawa M, Suzuki C, et al. GDNF-mediated signaling via RET tyrosine 1062 is essential for maintenance of spermatogonial stem cells. Genes Cells. 2008;13(4):365-74. doi:10.1111/j.1365-2443.2008.01171. 86. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002;3(5):383-94. doi:10.1038/nrn812 87. Accardo G, Conzo G, Esposito D, Gambardella C, Mazzella M, Castaldo F, et al. Genetics of medullary thyroid cancer: an overview. Int J Surg. 2017;41:(Suppl 1):S2-S6. doi:10.1016/j.ijsu.2017.02.064 88. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363(6428):458-60. doi:10.1038/363458a0 89. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore, TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2(7):851-6. doi:10.1093/hmg/2.7.851 90. Li SY, Ding YQ, Si YL, Ye MJ, Xu CM, Qi XP. 5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine. Front Endocrinol (Lausanne). 2020;11:543246. doi:10.3389/fendo.2020.543246 91. Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo). 2012;67(Suppl 1):69-75. doi:10.6061 clinics/2012(sup01)13 92. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol. 1995;15(3):1613-9. doi:10.1128/MCB.15.3.1613 93. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267(5196):381-3. doi:10.1126/science.7824936 94. Rothberg AE, Raymond VM, Gruber SB, Sisson J. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid. 2009;19(6):651-5. doi:10.1089/thy.2009.0021 95. Qi XP, Peng JZ, Yang XW, Cao Z-L, Yu X-H, Fang X-D, et al. The RET C611Y mutation causes MEN 2A and associated cutaneous. Endocr Connect. 2018;7(9):998-1005. doi:10.1530/EC-18-0220 96. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat. 2011;32(1):51-8. doi:10.0002/ humu.21385 97. Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens). 2009;8(1):23-8. doi:10.14310/horm.2002.1218 98. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA. 1994;91(4):1579-83. doi:10.1073/pnas.91.4.1579 99. Smith DP, Houghton C, Ponder BA. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene. 1997;15(10):1213-17. doi:10.1038/sj.onc.1201481 100. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575-9. doi:10.1001/jama.1996.03540190047028 101. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab. 1997;82(11):3902-4. doi:10.1210/jcem.82.11.4508 102. Mathiesen JS, Habra MA, Bassett JHD, Choudhury M, Balasubramanian SP, Howlett TA, et al. Risk profile of the RET A883F germline mutation: an international collaborative study. J Clin Endocrinol Metab. 2017;102(6):2069-74. doi:10.1210/jc.2016-3640 103. Songyang Z, Carraway KL 3rd, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995;373(6514):536-9. doi:10.1038/373536a0 104. Gujral TS, Singh VK, Jia Z, Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res. 2006;66(22):10741-9. doi:10.1158/0008-5472.CAN-06-3329 105. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem. 2006;281(44):33577-87. doi:10.1074/jbc. M605604200 106. Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallionet AS, al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res. 2006;66(20):10179-87. doi:10.1158/0008-5472.CAN-06-0884 107. Miyauchi A, Futami H, Hai N, Radzio-Andzelm E, Stone EA, McCallion AS, et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res. 1999;90(1):1-5. doi:10.1111/j.1349-7006.1999.tb00658.x 108. Iwashita T, Murakami H, Kurokawa K, Kawai K, Miyauchi A, Futami H, et al. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. Biochem Biophys Res Commun. 2000;268(3):804-08. doi:10.1006/ bbrc.2000.2227 109. Kameyama K, Okinaga H, Takami H. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed Pharmacother. 2004;58(6-7):345-7. doi:10.1016/j.biopha.2004.05.001 110. Nakao KT, Usui T, Ikeda M, Mori Y, Yamamoto T, Kawashima S-T, et al. Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis. Head Neck. 2013;35(12):E363-8. doi:10.1002/hed.23241 111. Mathew A, Latteyer S, Frank-Raue K, Moeller LC, Zwanziger D, Mengel M, et al. A Novel double RET E768D/L790F mutation associated with a MEN2B-Like phenotype. Thyroid. 2021;31(2):327-9. doi:10.1089/thy.2019.0472 112. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res. 1996;56(9):2167-70. 113. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer. 1995;12(3):209-12. doi:10.1002/gcc.2870120308 114. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1996;44(3):249-57. doi:10.1046/j.1365-2265.1996.681503.x 115. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi, F, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996;81(4):1619-22. doi:10.1210/jcem.81.4.8636377 116. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 2008;284(1-2):21-7. doi:10.1016/j.mce.2007.12.016 117. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93(3):682-7. doi:10.1210/jc.2007-1714 118. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009;100(11):1777-83. doi:10.1038/sj.bjc.6605056 119. Romei C, Ciampi R, Casella F, Tacito A, Torregrossa L, Ugolini C, et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget. 2018;9(11):9875-84. doi:10.18632/oncotarget.23986 120. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med. 1995;238(4):343-6. doi:10.1111/j.1365-2796.1995.tb01208.x 121. Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab. 2001;86(3):1104-9. doi:10.1210/jcem.86.3.7290 122. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003;138(4):409-16. doi:10.1001/archsurg.138.4.409 123. Milos IN, Frank-Raue K, Wohllk N, Maia AL, Pusiol E, Patocs A, et al. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. Endocr Relat Cancer. 2008;15(4):1035-41. doi:10.1677/ERC-08-0105 124. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab. 1998;83(2):487-91. doi:10.1210/jcem.83.2.4529 125. Puñales MK, Graf H, Gross JL, Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab. 2003;88(6):2644-9. doi:10.1210/jc.2002-021422 126. Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, et al. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011;21(2):189-92. doi:10.1089/thy.2010.0328 127. Schilling T, Bürck J, Sinn HP, Clemens A. Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer. 2001;95(1):62-6. doi:10.1002/1097-0215(20010120)95:13.0.co;2-1 128. Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R, et al. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid. 2012;22(5):476-81. doi:10.1089/thy.2011.0358 129. Raue F, Frank-Raue K. Update on multiple endocrine neoplasia type 2: focus on medullary thyroid carcinoma. J Endocr Soc. 2018;2(8):933-43.doi:10.1210/js.2018-00178 130. Lombardo F, Baudin E, Chiefari E, Arturi F, Bardet S, Caillou B, et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab. 2002;87(4):1674-80. doi:10.1210/jcem.87.4.8403 131. Lindskog S, Nilsson O, Jansson S, Illerskog A-C, Ysander L, Ahlman H, et al. Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618. Br J Surg. 2004;91(6):713-8. doi:10.1002/bjs.4457 132. Signorini PS, França MI, Camacho CP, Lindsey SC, Valente FOF, Kasamatsu TS, et al. A ten-year clinical update of a large RET p.Gly533Cys kindred with medullary thyroid carcinoma emphasizes the need for an individualized assessment of affected relatives. Clin Endocrinol (Oxf). 2014;80(2):235-45. doi:10.1111/cen.12264 133. Long KL, Etzel C, Rich T, et al. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Fam Cancer. 2017;16(2):283-9. doi:10.1007/s10689-016-9948-7 134. Machens A, Lorenz K, Weber F, Dralle H. Genotype-specific progression of hereditary medullary thyroid cancer. Hum Mutat. 2018;39(6):860-9. doi:10.1002/humu.23430 135. Mathiesen JS, Nielsen SG, Rasmussen ÅK, Kiss K, Wadt K, Hermann AP, et al. Variability in medullary thyroid carcinoma in ret l790f carriers: a case comparison study of index patients. Front Endocrinol. 2020;11(251):1-7. doi:10.3389/fendo.2020.00251 136. Colombo C, Minna E, Rizzetti MG, et al. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies. Orphanet J Rare Dis. 2015;10:25. doi:10.1186/s13023-015-0231-z 137. Cebrian A, Lesueur F, Martin S, et al. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(11):6268-6274. doi:10.1210/jc.2004-2449 138. Robledo M, Gil L, Pollán M, et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res. 2003;63(8):1814-1817. 139. Elisei R, Cosci B, Romei C, et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab. 2004;89(7):3579-3584. doi:10.1210/jc.2003-031898 140. Lebeault M, Pinson S, Guillaud-Bataille M, et al. Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers. Thyroid. 2017;27(12):1511-1522. doi:10.1089/thy.2016.0399 141. Magalhães PK, de Castro M, Elias LL, Soares EG, Maciel LM. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma. Thyroid. 2004;14(10):848-852. doi:10.1089/thy.2004.14.848 142. Wiench M, Wygoda Z, Gubala E, et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol. 2001;19(5):1374-1380. doi:10.1200/JCO.2001.19.5.1374 143. Sromek M, Czetwertyńska M, Skasko E, Zielińska J, Czapczak D, Steffen J. The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central. Poland. Endocr Pathol. 2010;21(3):178-185. doi:10.1007/s12022-010-9125-8 144. Siqueira DR, Romitti M, da Rocha AP, et al. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocr Relat Cancer. 2010;17(4):953-963. doi:10.1677/ERC-09-0312 145. Ceolin L, Siqueira DR, Ferreira CV, et al. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness. Eur J Endocrinol. 2012;166(5):847-854. doi:10.1530/EJE-11-1060 146. Machens A, Frank-Raue K, Lorenz K, Rondot S, Raue F, Dralle H. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Clin Endocrinol (Oxf). 2012;76(5):691-697. doi:10.1111/j.1365-2265.2011.04293.x 147. Zhang Y, Wang S, Chen X, Huang S, Li J. Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk. Tumour Biol. 2014;35(7):6641-6647. doi:10.1007/s13277-014-1878-0 148. Skalniak A, Trofimiuk-Müldner M, Przybylik-Mazurek E, Hubalewska-Dydejczyk A. Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma. Int J Mol Sci. 2021 Oct 30;22(21):11794. doi:10.3390/ijms222111794. 149. Berard I, Kraimps JL, Savagner F, et al. Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. Clin Genet. 2004;65(2):150-152. doi:10.1111/j.0009-9163.2004.00172.x 150. Baumgartner-Parzer SM, Lang R, Wagner L, et al. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?. J Clin Endocrinol Metab. 2005;90(11):6232-6236. doi:10.1210/jc.2005-1278 151. Wohllk, N; Soto, E; Bravo, M; Becker, P. G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients. Rev. Méd. Chile. 2005;133(4):397-402. http://dx.doi.org/10.4067/S0034-98872005000400001. 152. Weinhaeusel A, Scheuba C, Lauss M, et al. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma. Thyroid. 2008;18(12):1269-1276. doi:10.1089/thy.2008.0139 153. Sharma BP, Saranath D. RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients. J Biosci. 2011;36(4):603-611. doi:10.1007/s12038-011-9095-0 154. Lantieri F, Caroli F, Ceccherini I, Griseri P. The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study. Int J Cancer. 2013;132(12):2808-2819. doi:10.1002/ijc.27967 155. Rocha, AP; Magalhães, PK; Maia, AL; Maciel, LM. Genetic polymorphisms: implications in the pathogenesis of medullary thyroid carcinoma. Arq. Bras. Endocrinol. Metab. 2007; 51(5):723-730. https://doi.org/10.1590/S0004-27302007000500009 156. Ceolin, L.; Siqueira, D.R.; Romitti, M.; Ferreira, C.V.; Maia, A.L. Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms. Int. J. Mol. Sci. 2012;13(1):221-239. https://doi.org/10.3390/ijms13010221 157. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi:10.1038/gim.2015.30. 158. Brierley J, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumours. Chichester: Wiley; 2017. 159. Amodru V, Taieb D, Guerin C, Romanet P, Paladino N, Brue T, et al. MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocrine. 2020;69(3):496-503. doi:10.1007/s12020-020-02332-2. 160. Inabnet WB, Caragliano P, Pertsemlidis D. Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery. 2000;128(6):1007-1012. doi:10.1067/msy.2000.110846. 161. Rodriguez JM, Balsalobre M, Ponce JL, Ríos A, Torregrosa NM, Tebar J, et al. Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg. 2008;32(11):2520-6. doi:10.1007/s00268-008-9734-2. 162. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al. International RET Exon 10 Consortium. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat. 2011;32(1):51-8. doi:10.1002/humu.21385. PMID: 20979234. 163. Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, et al. MEN Consortium of Japan. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol. 2013;168(5):683-7. doi:10.1530/EJE-12-1106. 164. Ruiz-Ferrer M, Fernández RM, Antiñolo G, López-Alonso M, Eng C, Borrego S. A complex additive model of inheritance for Hirschsprung disease is supported by both RET mutations and predisposing RET haplotypes. Genet Med. 2006;8(11):704-10. doi:10.1097/01.gim.0000245632.06064.f1. 165. Frank-Raue K, Döhring J, Scheumann G, Rondot S, Lorenz A, Schulze E, et al. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour. Exp Clin Endocrinol Diabetes. 2010;118(8):550-3. doi:10.1055/s-0029-1241851. 166. Brandão LG, Cavalheiro BG, Junqueira CR. Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases. Clinics (Sao Paulo). 2009;64(9):849-56. doi:10.1590/S1807-59322009000900005. 167. Martins-Costa MC, Lindsey SC, Cunha LL, Carreiro-Filho FP, Cortez AP, Holanda ME, et al. A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals. Arch Endocrinol Metab. 2018;62(6):623-635. doi:10.20945/2359-3997000000088. 168. Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbecks Arch Surg. 1998;383(5):334-336. doi:10.1007/s004230050143. 169. Correia-Deur JE, Toledo RA, Imazawa AT, Lourenço DM Jr, Ezabella MC, Tavares MR, Toledo SP. Sporadic medullary thyroid carcinoma: clinical data from a university hospital. Clinics (Sao Paulo). 2009;64(5):379-86. doi:10.1590/s1807-59322009000500002. 170. Cavalheiro BG, Matos LL, Leite AK, Kulcsar MA, Cernea CR, Brandão LG. Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital. Arch Endocrinol Metab. 2016;60(5):472-478. doi:10.1590/2359-3997000000209. 171. Brandwein-Gensler M, Urken M, Wang B. Collision tumor of the thyroid: a case report of metastatic liposarcoma plus papillary thyroid carcinoma. Head Neck. 2004;26(7):637-41. doi:10.1002/hed.20024. 172. Rossi S, Fugazzola L, De Pasquale L, Braidotti P, Cirello V, Beck-Peccoz P, et al. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocr Relat Cancer. 2005;12(2):281-9. doi:10.1677/erc.1.00901. 173. Dikbas O, Duman AA, Guvendi GF. Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma in the Same Patient as a Collision Tumour. Case Rep Endocrinol. 2019;2019:4038628. doi:10.1155/2019/4038628. 174. Thomas A, Mittal N, Rane SU, Bal M, Patil A, Ankathi SK, Vaish R. Papillary and Medullary Thyroid Carcinomas Presenting as Collision Tumors: A Case Series of 21 Cases at a Tertiary Care Cancer Center. Head Neck Pathol. 2021;15(4):1137-1146. doi:10.1007/s12105-021-01323-7. 175. Mousa U, Gursoy A, Ozdemir H, Moray G. Medullary thyroid carcinoma in a patient with Hashimoto's thyroiditis diagnosed by calcitonin washout from a thyroid nodule. Diagn Cytopathol. 2013;41(7):644-6. doi:10.1002/dc.21850. 176. Zayed AA, Ali MK, Jaber OI, Suleiman MJ, Ashhab AA, Al Shweiat WM, et al. Is Hashimoto's thyroiditis a risk factor for medullary thyroid carcinoma? Our experience and a literature review. Endocrine. 2015;48(2):629-36. doi:10.1007/s12020-014-0363-2. 177. Dasgupta S, Chakrabarti S, Mandal PK, Das S. Hashimoto's Thyroiditis and Medullary Carcinoma of Thyroid. JNMA J Nepal Med Assoc. 2014;52(194):831-3. 178. Malpani S, Tandon A, Panwar H, Khurana U, Kapoor N, Behera G, Gupta V. Medullary thyroid carcinoma co-existent with Hashimoto's thyroiditis diagnosed by a comprehensive cytological approach. Diagn Cytopathol. 2020;48(4):386-389. doi:10.1002/dc.24373. 179. Maciel RMB, Maia AL. Global endocrinology: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review. Eur J Endocrinol. 2021;186(1):R15-R30. doi:10.1530/EJE-21-0753. 180. Maciel RMB, Camacho CP, Assumpção LVM, Bufalo NE, Carvalho AL, Carvalho GA, et al. Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study. Endocr Connect. 2019;8(3):289-298. doi:10.1530/EC-18-0506. 181. Siqueira DR, Ceolin L, Ferreira CV, Romitti M, Maia SC, Maciel LM, et al. Role of RET genetic variants in MEN2-associated pheochromocytoma. Eur J Endocrinol. 2014;170(6):821-8. doi:10.1530/EJE-14-0084. 182. Costa P, Domingues R, Sobrinho LG, Bugalho MJ. RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population. Endocrine. 2005;27(3):239-43. doi:10.1385/ENDO:27:3:239. 183. Hatanaka R. Rastreamento de variantes de significado desconhecido (VUS) no gene RET em indivíduos-controle e em pacientes com carcinoma medular de tireoide. [dissertação]. São Paulo: Faculdade de Medicina, Universidade de São Paulo, 2015. 184. Ministério da Saúde. Portaria nº 874 de 16 de maio de 2013. Institui a política nacional para a prevenção e controle do câncer na Rede de Atenção à Saúde das Pessoas com Doenças Crônicas no âmbito do Sistema Único de Saúde (SUS). Brasil: 2013. Disponível em: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt0874_16_05_2013.html; https://repositorio.ufba.br/handle/ri/36876

Διαθεσιμότητα: https://repositorio.ufba.br/handle/ri/36876

View record from BASE

12

Dissertation/ Thesis

Avaliação de genes auto inflamatórios em crianças com Síndrome Inflamatória Multissistêmica Pediátrica (SIM-P) associada à infecção pelo SARS-CoV-2 ; Genetic screening of autoinflammatory genes in Latin American Individuals with Multisystem Inflammatory Syndrome in Children (MIS-C) associated with SARS-CoV-2 infection

Συγγραφείς: São Pedro, Raquel Bispo de

Συνεισφορές: Oliveira, Pablo Rafael Silveira, orcid:0000-0001-9541-3737, http://lattes.cnpq.br/0858029972032771, Guedes, Carlos Eduardo Sampaio, orcid:0000-0003-1442-8625, http://lattes.cnpq.br/6898346030063073, Castro, Thiago Luiz de Paula, orcid:0000-0002-2869-5065, http://lattes.cnpq.br/1462921724686345, Lorenzo, Vivian Botelho, orcid:0000-0001-8020-051X, http://lattes.cnpq.br/9263801120056034

Θεματικοί όροι: Síndrome Inflamatória Multissistêmica Pediátrica (SIM-P), Genética, SARS-CoV-2, Auto inflamatório, Multisystem Inflammatory Syndrome in Children (MIS-C), Genetics, Auto inflammatory, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, CNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOGENETICA

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufba.br/handle/ri/38918

Διαθεσιμότητα: https://repositorio.ufba.br/handle/ri/38918

View record from BASE

13

Dissertation/ Thesis

Atividade biológica in vitro e in silico de complexos de metais de transição puros e nanoformulados ; Biological activity in vitro and in silico of pure and nanoformulated transition metal complexes

Συγγραφείς: Lino, Ricardo Campos

Συνεισφορές: Oliveira Júnior, Robson José de, http://lattes.cnpq.br/4537038370646907, Morelli, Sandra, http://lattes.cnpq.br/1661483102212717, Arruda, Alcione da Silva, http://lattes.cnpq.br/1624259149407787

Θεματικοί όροι: NLC, Docking molecular, Autofagia, Clivagem de DNA, Antitumoral, Metais de transição, Cobre, Molecular docking, Autophagy, DNA cleavage, Antitumor, Transition metals, Copper, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, Genética, Câncer - Tratamento

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufu.br/handle/123456789/35159; http://doi.org/10.14393/ufu.di.2022.231

Διαθεσιμότητα: https://repositorio.ufu.br/handle/123456789/35159
https://doi.org/10.14393/ufu.di.2022.231

View record from BASE

14

Participação de TP53 no prognóstico de câncer de mama HER2+ utilizando ferramentas de biologia computacional

Συγγραφείς: Castro, Yago Rafael Cagnoni de

Συνεισφορές: Rezende, Alexandre Azenha Alves de, http://lattes.cnpq.br/9751160400590652, Ferreira, Gabriela Lícia Santos, http://lattes.cnpq.br/9360602669902637, Calábria, Luciana Karen, http://lattes.cnpq.br/5894293638314281

Θεματικοί όροι: Tumor protein 53, ERBB2, Bioinformática, Marcador genético molecular, Neoplasia, Supressor tumoral, Mutação, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::MUTAGENESE, CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA::BIOLOGIA MOLECULAR

Περιγραφή αρχείου: application/pdf

Relation: CASTRO, Yago Rafael Cagnoni de. Participação de TP53 no prognóstico de câncer de mama HER2+ utilizando ferramentas de biologia computacional. 2022. 50 f. Trabalho de Conclusão de Curso (Graduação em Ciências Biológicas) – Universidade Federal de Uberlândia, Ituiutaba, 2022.; https://repositorio.ufu.br/handle/123456789/35540

Διαθεσιμότητα: https://repositorio.ufu.br/handle/123456789/35540

View record from BASE

15

Dissertation/ Thesis

Caracterização dos aptâmeros D4 e R4 como ferramentas teranósticas no câncer de próstata ; Characterization of D4 and R4 aptamers as theranostic tools in prostate cancer

Συγγραφείς: Fernández, Esther Campos

Συνεισφορές: Goulart, Vivian Alonso, http://lattes.cnpq.br/6846069044649305, Pesquero, João Bosco, http://lattes.cnpq.br/0856630824759511, Neves, Adriana Freitas, http://lattes.cnpq.br/2984939300978146, Nicolau Junior, Nilson, http://lattes.cnpq.br/0821186870496558, Araújo, Thaise Gonçalves de, http://lattes.cnpq.br/3348615812243880

Θεματικοί όροι: aptâmeros, biópsia líquida, câncer de próstata, células tumorais circulantes, diagnostics, biosensors, nanotechnology, prostate cancer, aptamers, theranostics, CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA::BIOLOGIA MOLECULAR, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, Genética, Próstata - Câncer, Câncer - Diagnóstico, Biópsia, Câncer - Tratamento

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufu.br/handle/123456789/36646; http://doi.org/10.14393/ufu.te.2022.5048

Διαθεσιμότητα: https://repositorio.ufu.br/handle/123456789/36646
https://doi.org/10.14393/ufu.te.2022.5048

View record from BASE

16

Estudo do receptor CB1 utilizando ferramentas de biologia computacional: avaliação do uso do Danio rerio como modelo biológico para o estudo da memória

Συγγραφείς: Mateus, Wesley dos Santos

Συνεισφορές: Rezende, Alexandre Azenha Alves de, http://lattes.cnpq.br/9751160400590652, Wolkers, Carla Patrícia Bejo, http://lattes.cnpq.br/4709185620670481, Serra, Monica, http://lattes.cnpq.br/0963248529433149, Marson, Leonardo Augusto, http://lattes.cnpq.br/7610300332897645, Wolkers, Carla Patricia Bejo

Θεματικοί όροι: Canabinoides, Endocannabinoid system, Homologia, Cannabinoids, Receptor CB1, CB1 receptor, Sistema endocanabinoide, Homology, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA, CNPQ::CIENCIAS BIOLOGICAS

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufu.br/handle/123456789/34454

Διαθεσιμότητα: https://repositorio.ufu.br/handle/123456789/34454

View record from BASE

17

Dissertation/ Thesis

Estudo da relação entre PARP-1 e adiponectina em pessoas com lipodistrofia generalizada congênita tipo 2

Συγγραφείς: Soares, Luisa Pessoa

Συνεισφορές: Campos, Julliane Tamara Araújo de Melo, orcid:0000-0003-4803-1423, http://lattes.cnpq.br/2228937168510509, orcid:0000-0002-8501-5521, http://lattes.cnpq.br/3504274193684794, Lima, Josivan Gomes de, orcid:0000-0002-1627-7018, http://lattes.cnpq.br/6456654111946909, Araujo Junior, Raimundo Fernandes de, http://lattes.cnpq.br/1903940945895093

Θεματικοί όροι: CGL, PARP-1, Adiponectina, Regulação gênica, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufrn.br/handle/123456789/51005

Διαθεσιμότητα: https://repositorio.ufrn.br/handle/123456789/51005

View record from BASE

18

Método de descelularização de pele de tilápia (Oreochromis sp.)

Συγγραφείς: Souza, Nayara dos Santos

Συνεισφορές: Maranduba, Carlos Magno da Costa, http://lattes.cnpq.br/4763153859701731, Munk Pereira, Michele, http://lattes.cnpq.br/8094404295191170, Trevizani, Marízia, http://lattes.cnpq.br/1543665156752981, Leal, Laís Lopardi, http://lattes.cnpq.br/7223029548923303

Θεματικοί όροι: Queimaduras, Pele de Tilápia, Descelularização, Engenharia de Tecidos, Burns, Tilapia Skin, Decellularization, Tissue Engineering, CNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA

Περιγραφή αρχείου: application/pdf

Relation: https://repositorio.ufjf.br/jspui/handle/ufjf/14601

Διαθεσιμότητα: https://repositorio.ufjf.br/jspui/handle/ufjf/14601

View record from BASE

19

Dissertation/ Thesis

Associação entre densidade mineral óssea, polimorfismos do gene da osteoprotegerina, do ligante do Rank, e parâmetros metabólicos e antropométricos em idosas de Salvador, Bahia ; Association among bone mineral density, polymorphisms of osteoprotegerin and RANK ligand genes, and metabolic and anthropometric parameters in elderly women in Salvador, Bahia

Συγγραφείς: Almeida, Daniela Oliveira de

Συνεισφορές: Lemaire, Denise Carneiro, orcid:0000-0001-7897-4401, http://lattes.cnpq.br/3842936562682691, Magalhães, Manuela Oliveira de Cerqueira, orcid:0000-0003-1758-1377, http://lattes.cnpq.br/8615745290914010, Jesus, Rosângela Passos de, http://lattes.cnpq.br/2925811144406467, Peixoto, Josecy Maria de Souza, Freitas, Juliana Côrtes de